Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

IMPROVing lifElong health and development for children and adults born very PRETERM – observational studies to enhance randomised trials for comparative effectiveness research

Project description

Taking care of very preterm infants

Each year, over 50 000 infants are born very preterm (before 32 weeks of gestation) in Europe and face lifelong challenges such as cognitive impairment, respiratory illnesses, and psychiatric disorders. Despite increases in survival rates, long-term health outcomes have not improved. The need for evidence-based, cost-effective, and accessible treatments is urgent, but research is hindered by ethical and logistic barriers. Τhe EU-funded IMPROVE PRETERM project brings together diverse multidisciplinary teams from 13 countries to evaluate interventions like corticosteroid treatments, follow-up programmes, and vaccine strategies. Outputs include tools for assessing children’s development and a sustainable data platform designed to optimise the use of population data for research in healthcare, social, and educational policy that will enhance health and well-being for very preterm individuals and their families.

Objective

IMPROVE PRETERM aims to optimise the discovery and use of cost-effective, affordable and accessible interventions at birth and in early childhood to mitigate the adverse consequences of very preterm birth (VPT; <32 weeks of gestation). These include cerebral palsy, motor and cognitive impairment, visual/auditory deficits, respiratory illnesses, and psychiatric disorders and affect lifelong health and wellbeing. The VPT population is of high public health need as long-term outcomes are not improving despite increased survival, due to logistic and ethical challenges in generating evidence on effective interventions, leading to unstandardised and suboptimal care.
Multidisciplinary, geographically diverse (13 country) research teams, working with key stakeholders (families, patients, health professionals and policymakers) will leverage advances in causal inference methods and optimise existing data sources (trials, cohort studies, birth registers, neonatal networks) within an established European federated platform for Comparative Effectiveness Research (CER). Use Cases will compare high-priority interventions: 1) antenatal and postnatal corticosteroid treatment, 2) follow-up and intervention programmes and 3) vaccine strategies. Capacity-building outputs will be: 1) a generalisable Lifecourse CER Framework (core outcome sets, methodological guidelines for causal inference and economic evaluation); 2) an open-source validated and standardised parent-report tool for assessing child development; 3) data sources (>30) and analytic methods on a sustainable, privacy-preserving FAIR platform.
IMPROVE PRETERM will consider a broad range of patient-valued outcomes, extending current assessment periods beyond infancy, to provide holistic, cost-effective solutions for high-quality CER. Outputs will improve the use of evidence-based care by clinicians and policymakers, reduce the preventable health burden and promote better quality of life for VPT individuals and their families.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2024-DISEASE-03-two-stage

See all projects funded under this call

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 788 252,50
Address
RUE DE TOLBIAC 101
75654 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
No data

Participants (18)

Partners (1)